10-Q: Rafael Holdings Reports Q1 2025 Results, Posts Net Loss Amidst Strategic Shift Towards Cyclo Therapeutics Merger

Rafael Holdings reported a net loss of $9 million for the quarter ended October 31, 2024, as it focuses on a planned merger with Cyclo Therapeutics and evaluates its existing assets.

Summary

• Rafael Holdings reported a consolidated net loss of $9.211 million for the three months ended October 31, 2024, compared to a net loss of $3.760 million for the same period in 2023.
• The company's revenue for the quarter was $128 thousand, primarily from infusion technology and real estate rentals, compared to $68 thousand in the same period last year.
• Operating expenses increased to $3.844 million, up from $2.478 million in the prior year, driven by higher research and development costs and general and administrative expenses.
• The company's cash and cash equivalents stood at $8.159 million, with available-for-sale securities valued at $46.138 million as of October 31, 2024.
• Rafael Holdings is in the process of a planned merger with Cyclo Therapeutics, which is expected to close in the first calendar quarter of 2025.
• The company is evaluating its operating entities to focus resources on core assets, particularly the Trappsol Cyclo clinical program.
• The company has provided $9 million in convertible notes to Cyclo Therapeutics during the quarter.
• The company has sold its investments in available-for-sale securities and cash equivalents for cash proceeds totaling $52.9 million subsequent to the quarter end.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive aspects, such as the increased cash position and the planned merger, the significant net loss, increased operating expenses, and unrealized losses on investments create a negative sentiment. The company is in a transitional phase, and its future success is highly dependent on the outcome of the merger and the clinical program.

Positives

• The company's cash and cash equivalents increased to $8.159 million from $2.675 million at the end of the previous quarter.
• The company has secured $52.9 million in cash proceeds from the sale of available-for-sale securities and cash equivalents subsequent to the quarter end.
• The company is actively pursuing a merger with Cyclo Therapeutics, which could lead to a focused clinical program.
• The company is evaluating its operating entities to ensure resources are focused on core assets.

Negatives

• The company reported a significant net loss of $9.211 million for the quarter.
• Operating expenses increased significantly compared to the same period last year.
• The company recognized a substantial unrealized loss of $4.365 million on its investment in Cyclo Therapeutics.
• The company recognized an unrealized loss of $1.588 million on convertible notes receivable due from Cyclo.
• The company's revenue remains relatively low at $128 thousand for the quarter.

Risks

• The company's planned merger with Cyclo Therapeutics is subject to shareholder approvals and other closing conditions.
• The company's future success is heavily dependent on the success of the Trappsol Cyclo clinical program.
• The company's financial performance is subject to fluctuations in the fair value of its investments.
• The company's ability to achieve profitability is uncertain given the current level of expenses and losses.
• The company is exposed to risks associated with its investments in early-stage pharmaceutical companies.

Future Outlook

The company intends to focus its efforts on making Trappsol Cyclo its lead clinical program upon closing of the planned merger with Cyclo, and will fund the TransportNPC phase III clinical trial to its interim analysis in the middle of 2025. The company will then make a determination as to whether or not to file an NDA for Trappsol Cyclo.

Management Comments

• The company is currently evaluating its operating entities (or portfolio of assets) to ensure the future focus of its resources on core assets and specifically the Trappsol Cyclo clinical and development efforts.
• The company expects its balance of cash and cash equivalents, and available-for-sale securities, to be sufficient to meet its obligations for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.

Industry Context

The company's focus on clinical-stage pharmaceutical companies and its planned merger with Cyclo Therapeutics reflect a broader trend in the biotechnology industry towards consolidation and the development of novel therapies for unmet medical needs. The company's investment in cancer metabolism-based therapeutics also aligns with the growing interest in targeted therapies.

Comparison to Industry Standards

• The company's revenue of $128 thousand is significantly lower than many established pharmaceutical and biotechnology companies, which often report revenues in the millions or billions of dollars.
• The company's net loss of $9.211 million is substantial, and it is not uncommon for early-stage biotech companies to operate at a loss while developing their products.
• The company's cash position of $8.159 million, while improved from the previous quarter, is relatively modest compared to larger companies in the sector, which often have hundreds of millions or billions in cash reserves.
• The company's investment in Cyclo Therapeutics and its focus on Trappsol Cyclo are similar to other biotech companies that are developing treatments for rare diseases, which often have high potential but also high risks.
• The company's decision to curtail early-stage development efforts at Barer is a common strategy for companies that are prioritizing specific clinical programs and seeking to reduce costs.

Related Party Transactions

• The company leased space to related parties, which represented approximately 21% of the company's total revenue for the three months ended October 31, 2024.
• IDT Corporation, a related party, was billed approximately $70 thousand for services during the three months ended October 31, 2024.
• The company invoiced IDT approximately $27 thousand for each of the three months ended October 31, 2024 for office rent and parking.
• During the three months ended October 31, 2024, the company paid Sam Beyda, who serves as Chief Executive Officer and a Director of Day Three and is Howard Jonas son-in-law, a salary of $41.7 thousand and bonus of $23.7 thousand.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and the uncertainty surrounding the merger with Cyclo Therapeutics.
• Employees may be affected by the company's evaluation of its operating entities and the potential for restructuring.
• Customers of Day Three Labs may see changes in the company's offerings as Rafael Holdings evaluates its prospects.
• Creditors of Cornerstone may be impacted by the company's review of Cornerstone's current efforts and prospects.

Next Steps

• The company will seek shareholder approval for the merger with Cyclo Therapeutics.
• The company will continue to evaluate its operating entities to focus resources on core assets.
• The company will fund the TransportNPC phase III clinical trial to its interim analysis in the middle of 2025.
• The company will make a determination as to whether or not to file an NDA for Trappsol Cyclo.

Key Dates

Keywords

Rafael Holdings, Cyclo Therapeutics, Merger, Trappsol Cyclo, Niemann-Pick Disease Type C1, Pharmaceuticals, Biotechnology, Clinical Trials, Financial Results, Investment, Convertible Notes, LipoMedix, Cornerstone, Day Three Labs, Real Estate, Infusion Technology